Sunosi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
T/0022 
Transfer of Marketing Authorisation 
21/08/2023 
22/09/2023 
SmPC, 
Labelling and 
PL 
IAIN/0020 
B.II.b.1.a - Replacement or addition of a 
13/06/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
site 
IA/0019 
A.7 - Administrative change - Deletion of 
22/03/2023 
n/a 
manufacturing sites 
IAIN/0018 
B.II.b.2.c.1 - Change to importer, batch release 
13/12/2022 
22/09/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10831
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
solriamfetol 
T/0016 
Transfer of Marketing Authorisation 
26/08/2022 
07/10/2022 
SmPC, 
Labelling and 
PL 
IB/0017 
B.II.b.4.e - Change in the batch size (including batch 
03/10/2022 
n/a 
size ranges) of the finished product - More than 10-
fold increase compared to the originally approved 
batch size for immediate release (oral) 
pharmaceutical form 
IA/0015/G 
This was an application for a group of variations. 
07/07/2022 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
compared to the originally approved batch size 
PSUSA/10831
Periodic Safety Update EU Single assessment - 
07/04/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
solriamfetol 
IA/0013/G 
This was an application for a group of variations. 
13/12/2021 
07/10/2022 
SmPC, 
Labelling and 
PL 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10831
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
solriamfetol 
IB/0011 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/10/2021 
07/10/2022 
SmPC 
To change the shelf-life in section 6.3 of the Summary of 
life of the finished product - As packaged for sale 
Product Characteristics from 4 to 5 years. 
(supported by real time data) 
II/0009 
Update of section 4.8 of the SmPC in order to add 
01/07/2021 
19/10/2021 
SmPC and PL 
The list of adverse drug reactions in section 4.8 of the 
hypersensitivity reactions to the list of adverse drug 
reactions (ADRs) following confirmation of a post 
marketing safety signal for hypersensitivity. The 
Package Leaflet is updated accordingly. In addition, 
the MAH took the opportunity to implement editorial 
SmPC is updated following confirmation of a post marketing 
safety signal for hypersensitivity reactions which have 
occurred with one or more of the following: rash 
erythematous, rash, urticarial. 
For more information, please refer to the Summary of 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes and to bring the PI in line with the latest 
Product Characteristics. 
QRD template version 10.2. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10831
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
solriamfetol 
IA/0008 
B.II.b.2.a - Change to importer, batch release 
15/12/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0006 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
18/11/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10831
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
solriamfetol 
IA/0005/G 
This was an application for a group of variations. 
21/09/2020 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.f - Change in test procedure for the finished 
product - To reflect compliance with the Ph. Eur. and 
remove reference to the outdated internal test 
method and test method number 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
II/0004 
C.I.13 - Other variations not specifically covered 
10/09/2020 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0003/G 
This was an application for a group of variations. 
21/08/2020 
19/10/2021 
SmPC and 
Annex II 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.II.d.2.z - Change in test procedure for the finished 
30/03/2020 
n/a 
product - Other variation 
Page 6/6 
 
 
 
 
 
 
 
 
 
